Current Pharmaceutical Design, 20(8), 1138-1145
Sci Rep (2017) 7(1):8933
But it would take another six months before the FDA closed the business down
Kops GJPL, Dansen TB, Polderman PE, Saarloos I, Wirtz KWA, Coffer PJ, et al
However, that's not strictly accurate
To obtain additional restraints for structural model determination of the p53 TAD2 -FOXO4 FH complex, we determined paramagnetic relaxation enhancements (PREs) for a set of 7 complexes containing spin-labeled (SL) samples ( 15 N-labeled FOXO4 FH + S46C-SL p53 TAD2 , 15 N-labeled FOXO4 FH + Q52C-SL p53 TAD2 , 15 N-labeled p53 TAD2 + Q112C-SL FOXO4 FH , 15 N-labeled p53 TAD2 + D140C-SL FOXO4 FH , 15 N-labeled p53 TAD2 + N145C-SL FOXO4 FH , 15 N-labeled p53 TAD2 + S159C-SL FOXO4 FH , 15 N-labeled p53 TAD2 + S162C-SL FOXO4 FH )